Skip to main content
SpringerLink
Log in

Small Cell Carcinoma

  • Chapter
Molecular Pathology of Lung Diseases

Part of the book series: Molecular Pathology Library ((MPLB,volume 1))

  • 2116 Accesses

Abstract

Small cell carcinoma is defined as a malignant epithelial tumor consisting of small cells with scant cytoplasm, defined cytoplasmic border, typical finely granular “salt and pepper” nuclear chromatin pattern, and inconspicuous or absent nucleoli. Small cell carcinoma is characterized by extensive necrosis, a high mitosis rate, and conspicuous nuclear molding. The criteria of the definition of small cell carcinoma have not changed from the original World Health Organization classification to the revised ones.1,2 The definition is based essentially on cytologic criteria, and the most discriminating criteria probably are the chromatin pattern and the very high nuclear to cytoplasmic ratio (8 to 9/10) beyond cell size. Fortunately, the definition of small cell lung carcinoma (SCLC) did not change so that the literature on clinical behavior, molecular biology, molecular pathology, and drug sensitivity are still relevant. The only major change between the recent and previous classifications resides in the abandonment of the variant intermediate cell type of oat cell carcinoma, essentially because of a lack of clinical and therapeutic differences.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Travis WD, Colby TV, Corrin B, et al. WHO Histological Classification of Tumours. Histological Typing of Lung and Pleural Tumours, 3rd ed. Berlin: Springer-Verlag; 1999.

    Google Scholar 

  2. Travis WD, Brambilla E, Muller-Hemerlink HK, Harris CC, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press; 2004.

    Google Scholar 

  3. Nicholson SA, Beasley MB, Brambilla E, et al. Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol 2002;26:1184–1197.

    Article  PubMed  Google Scholar 

  4. Lantuejoul S, Moro D, Michalides RJ, et al. Neural cell adhesion molecules (NCAM) and NCAM-PSA expression in neuroendocrine lung tumors. Am J Surg Pathol 1998;22:1267–1276.

    Article  CAS  PubMed  Google Scholar 

  5. Sturm N, Rossi G, Lantuejoul S, et al. Expression of thyroid transcription factor-1 (TTF-1) in the spectrum of neuroendocrine cell lung proliferations with special interest in carcinoids. Hum Pathol 2002;33(2):175–182.

    Article  PubMed  Google Scholar 

  6. Halliday BE, Slagel DD, Elsheikh TE, et al. Diagnostic utility of MIC-2 immunocytochemical staining in the differential diagnosis of small blue cell tumors. Diagn Cytopathol 1998;19:410–416.

    Article  CAS  PubMed  Google Scholar 

  7. Lumadue JA, Askin FB, Perlman EJ. MIC2 analysis of small cell carcinoma. Am J Clin Pathol 1994;102:692–694.

    CAS  PubMed  Google Scholar 

  8. Pelosi G, Leon ME, Veronesi G, et al. Decreased immunoreactivity of CD99 is an independent predictor of regional lymph node metastases in pulmonary carcinoid tumors. J Thorac Oncol 2006;1(5):468–477.

    Article  PubMed  Google Scholar 

  9. Balsara BR, Testa JR. Chromosomal imbalances in human lung cancer. Oncogene 2002;21:6877–6883.

    Article  CAS  PubMed  Google Scholar 

  10. Petersen I, Langreck H, Wolf G, et al. Small-cell lung cancer is characterized by a high incidence of deletions on chromosomes 3p, 4q, 5q, 10q, 13q and 17. Br J Cancer 1997;75(1):79–86.

    CAS  PubMed  Google Scholar 

  11. Petersen I, Hidalgo A, Petersen S, et al. Chromosomal imbalances in brain metastases of solid tumors. Brain Pathol 2000;10:395–401.

    Article  CAS  PubMed  Google Scholar 

  12. Watkins DN, Berman DM, Burkholder SG, et al. Hedgehog signaling within airway epithelial progenitors and in small cell lung cancer. Nature 2003;422:313–317.

    Article  CAS  PubMed  Google Scholar 

  13. Borges M, Linnoila RI, van de Velde HJ, et al. An achaetescute homologue essential for neuroendocrine differentiation in the lung. Nature 1997;386:852–855.

    Article  CAS  PubMed  Google Scholar 

  14. Ito T, Udaka N, Yazawa T, et al. Basic helix-loop-helix transcription factors regulate the neuroendocrine differentiation of fetal mouse pulmonary epithelium. Development 2000;127:3913–3921.

    CAS  PubMed  Google Scholar 

  15. Linnoila RI, Zhao B, DeMayo JL, et al. Constitutive achaetescute homologue-1 promotes airway dysplasia and lung neuroendocrine tumors in transgenic mice. Cancer Res 2000;60:4005–4009.

    CAS  PubMed  Google Scholar 

  16. Jiang SX, Kameya T, Asamura H, et al. hASH1 expression is closely correlated with endocrine phenotype and differentiation extent in pulmonary neuroendocrine tumors. Mod Pathol 2004;17:222–229.

    Article  CAS  PubMed  Google Scholar 

  17. Gazzeri S, Brambilla E, Caron De Fromentel C, et al. p53 genetic abnormalities and myc activation in human lung carcinomas. Int J Cancer 1994;58:24–32.

    Article  CAS  PubMed  Google Scholar 

  18. Brambilla E, Negoescu A, Gazzeri S, et al. Apoptosis-related factors P53, Bcl2, and Bax in neuroendocrine lung tumors. Am J Pathol 1996;149:1941–1952.

    CAS  PubMed  Google Scholar 

  19. Jiang SX, Kameya T, Sato Y, et al. Bcl2 protein expression in lung cancer and close correlation with neuroendocrine differentiation. Am J Pathol 1996;148:837–846.

    CAS  PubMed  Google Scholar 

  20. Gastman BR, Atarshi Y, Reichert TE, et al. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res 1999;59:5356–5364.

    CAS  PubMed  Google Scholar 

  21. Ungefroren H, Voss M, Jansen M, et al. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. Cancer Res 1998;58:1741–1749.

    CAS  PubMed  Google Scholar 

  22. Viard-Leveugle I, Veyrenc S, French LE, et al. Frequent loss of Fas expression and function in human lung tumors with overexpression of FasL in small cell lung carcinoma. J Pathol 2003;(201)2:268–277.

    Article  CAS  Google Scholar 

  23. Shivapurkar N, Toyooka S, Eby MT, et al. Differential inactivation of caspase-8 in lung cancer. Cancer Biol Ther 2002;1(1):54–58.

    Google Scholar 

  24. Holler N, Zaru R, Micheau O, et al. Fas triggers an alternative caspase 8-independent cell death pathway using kinase RIP as effector molecule. Nat Immunol 2000;1:489–495.

    Article  CAS  PubMed  Google Scholar 

  25. Cagle PT, El-Naggar AK, Xu HJ, et al. Differential retinoblastoma protein expression in neuroendocrine tumors of the lung. Am J Pathol 1997;150:393–400.

    CAS  PubMed  Google Scholar 

  26. Gouyer V, Gazzeri S, Bolon I, et al. Mechanism of retinoblastoma gene inactivation in the spectrum of neuroendocrine lung tumors. Am J Respir Cell Mol Biol 1998;18:188–196.

    CAS  PubMed  Google Scholar 

  27. Yuan J, Knorr J, Altmannsberger M, et al. Expression of p16 and lack of pRB in primary small cell lung cancer. J Pathol 1999;189:358–362.

    Article  CAS  PubMed  Google Scholar 

  28. Harbour JW, Lai SL, Whang-Peng J, et al. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science 1988;241:353–357.

    Article  CAS  PubMed  Google Scholar 

  29. Dosaka-Akita H, Cagle PT, Hiroumi H, et al. Differential retinoblastoma and p16(INK4) protein expression in neuroendocrine tumors of the lung. Cancer 2000;88:550–556.

    Article  CAS  PubMed  Google Scholar 

  30. Kratzke RA, Greatens TM, Rubins JB, et al. Rb and p16INK4 expression in resected non small cell lung tumors. Cancer Res 1996;56:3415–3420.

    CAS  PubMed  Google Scholar 

  31. Gazzeri S, Gouyer V, Vour’ch C, et al. Mechanism of p16INK4A inactivation in non small-cell lung cancers. Oncogene 1998;16(4):497–505.

    Article  CAS  PubMed  Google Scholar 

  32. Beasley MB, Lantuejoul S, Abbondanzo S, et al. The p16/cyclin D1/Rb pathway in neuroendocrine tumors of the lung. Hum Pathol 2003;34(2):136–142.

    Article  CAS  PubMed  Google Scholar 

  33. Sherr CJ. Tumour surveillance via the ARF-p53 pathway. Genes Dev 1998;12:2984–2991.

    Article  CAS  PubMed  Google Scholar 

  34. Eymin B, Leduc C, Coll JL, et al. P14ARF induces G2 arrest and apoptosis independently of p53 leading to regression of tumors established in nude mice. Oncogene 2003;22:1822–1835.

    Article  CAS  PubMed  Google Scholar 

  35. Hemmati PG, Gillissen B, von Haefen C, et al. Adenovirus-mediated overexpression of p14(ARF) induces p53 and Bax-independent apoptosis. Oncogene 2002;21:3149–3161.

    Article  CAS  PubMed  Google Scholar 

  36. Weber JD, Jeffers JR, Rehg JE, et al. p53-independent functions of the p19(ARF) tumor suppressor. Genes Dev 2000;14:2358–2365.

    Article  CAS  PubMed  Google Scholar 

  37. Eymin B, Claverie P, Salon C, et al. p14ARF activates a Tip60-dependent ATM/ATR/CHK pathway in response to genotoxic stresses. Mol Cell Biol 2006;26(11):4339–4350.

    Article  CAS  PubMed  Google Scholar 

  38. Gazzeri S, Della Valle V, Chaussade L, et al. The human p19ARF protein encoded by the β transcript of the p16INK4 gene is frequently lost in small cell lung tumors. Cancer Res 1998;58:3926–3931.

    CAS  PubMed  Google Scholar 

  39. Eymin B, Claverie P, Salon C, et al. P14ARF triggers G2 arrest through ERK-mediated Cdc25C phosphorylation, ubiquitination and proteasomal degradation. Cell Cycle 2006;5(7):759–765.

    CAS  PubMed  Google Scholar 

  40. Chen J, Marechal V, Levine AJ. Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol 1993;13:4107–4114.

    CAS  PubMed  Google Scholar 

  41. Momand J, Zambetti GP, Olson DC, et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237–1245.

    Article  CAS  PubMed  Google Scholar 

  42. Oliner JD, Pietenpol JA, Thiagalingam S, et al. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993;362:857–860.

    Article  CAS  PubMed  Google Scholar 

  43. Haupt Y, Maya R, Kazaz A, et al. Mdm2 promotes the rapid degradation of p53. Nature 1997;387:296–299.

    Article  CAS  PubMed  Google Scholar 

  44. Tao W, Levine AJ. Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proc. Natl Acad Sci USA 1999;96:3077–3080.

    Article  CAS  Google Scholar 

  45. Weber JD, Taylor LJ, Roussel MF, et al. Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol 1999;1:20–26.

    Article  CAS  PubMed  Google Scholar 

  46. Cordon-Cardo C, Latres E, Drobnjak M, et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994;54:794–799.

    CAS  PubMed  Google Scholar 

  47. Eymin B, Gazzeri S, Brambilla C, et al. Distinct pattern of E2F1 expression in human lung tumors: E2F1 is upregulated in small cell lung carcinoma. Oncogene 2001;20:1678–1687.

    Article  CAS  PubMed  Google Scholar 

  48. Zabarovsky ER, Lerman MI, Minna JD. Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene 2002;21:6915–6935.

    Article  CAS  PubMed  Google Scholar 

  49. Sozzi G, Pastorino U, Moiraghi L, et al. Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res 1998;58:5032–5037.

    CAS  PubMed  Google Scholar 

  50. Sard L, Accornero P, Tornielli S, et al. The tumor suppressor gene FHIT is involved in the regulation of apoptosis and cell cycle control. Proc Natl Acad Sci USA 1999;96:8489–8492.

    Article  CAS  PubMed  Google Scholar 

  51. Dammann R, Li C, Yoon JH, et al. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. 52. Nat Genet 2000;25:315–319.

    Article  CAS  PubMed  Google Scholar 

  52. Burbee DG, Forgacs E, Zochbauer-Muller S, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001;93:691–699.

    Article  CAS  PubMed  Google Scholar 

  53. Virmani AK, Rathi A, Zöchbauer-Müller S, et al. Promoter methylation and silencing of the retinoic acid receptor-β gene in lung carcinomas. J Natl Cancer Inst 2000;92:1303–1307.

    Article  CAS  PubMed  Google Scholar 

  54. Holt SE, Shay JW. Role of telomerase in cellular proliferation and cancer. J Cell Physiol 1999;180:10–18.

    Article  CAS  PubMed  Google Scholar 

  55. Lantuejoul S, Soria JC, Lorimier P, et al. Differential expression of telomerase reverse transcriptase (hTERT) in lung tumors. Br J Cancer 2004;90:1222–1229.

    Article  CAS  PubMed  Google Scholar 

  56. Hiyama K, Hiyama E, Ishioka S, et al. Telomerase activity in small cell and non small cell lung cancers. J Natl Cancer Inst 1995;87:895–902.

    Article  CAS  PubMed  Google Scholar 

  57. Albanell J, Lonardo F, Rush V, et al. High telomerase activity in primary lung cancers: association with increased cell proliferation rates and advanced pathologic stage. J Natl Cancer Inst 1997;89:1609–1615.

    Article  CAS  PubMed  Google Scholar 

  58. Gomez-Roman JJ, Fontalba Romero A, Sanchez Castro L, et al. Telomerase activity in pulmonary neuroendocrine tumours. Am J Surg Pathol 2000;24:417–421.

    Article  CAS  PubMed  Google Scholar 

  59. Lantuejoul S, Salon C, Soria JC, et al. Telomerase expression in lung preneoplasia and neoplasia. Int J Cancer 2007;120:1835–1841.

    Article  CAS  PubMed  Google Scholar 

  60. Decaussin M, Sartelet H, Robert C, et al. Expression of vascular endothelial growth factor (VEGF) and its receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non small cell lung carcinoma (NSCLC): correlation with angiogenesis and survival. J. Pathol 1999;188:369–377.

    Article  CAS  Google Scholar 

  61. Tian X, Song S, Wu J, et al. Vascular endothelial growth factor: acting as an autocrine growth factor for human gastric adenocarcinoma cell MGC803. Biochem Biophys Res Commun 2001;286:505–512.

    Article  CAS  PubMed  Google Scholar 

  62. Lantuejoul S, Constantin B, Drabkin H, et al. Expression of VEGF, semaphorin SEMA3F and their common receptors neuropilins NP1 and NP2 in preinvasive bronchial lesions, lung tumors and cell lines. J Pathol 2003;200:336–347.

    Article  CAS  PubMed  Google Scholar 

  63. Compernolle V, Brusselmans K, Acker T, et al. Loss of HIF-2α and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nature Med 2 2002;(8)7:702–710.

    CAS  Google Scholar 

  64. Kusy S, Nasarre P, Chan D, et al. Selective suppression of in vivo tumorigenicity by semaphoring SEMA3F in lung cancer cells. Neoplasia 2005;7(5):457–465.

    Article  CAS  PubMed  Google Scholar 

  65. Salon C, Moro D, Lantuejoul S, et al. The E-cadherin/β-catenin adhesion complex in neuroendocrine tumors of the lung: a suggested role upon local invasion and metastasis. Hum Pathol 2004;35(9):1148–1155.

    Article  CAS  PubMed  Google Scholar 

  66. Salon C, Lantuejoul S, Eymin B, et al. The E-cadherin-β-catenin complex and its implication in lung cancer progression and prognosis. Future Oncol 2005;1(5):649–660.

    Article  CAS  PubMed  Google Scholar 

  67. Clavel CE, Nollet F, Berx G, et al. Expression of the Ecadherin-catenin complex in lung neuroendocrine tumours. J Pathol 2001;194:20–26.

    Article  CAS  PubMed  Google Scholar 

  68. Heldin CH, Ostman A, Ronnstrand L. Signal transduction via platelet-derived growth factor receptors. Biochim Biophys Acta 1998;1378:F79–F113.

    CAS  PubMed  Google Scholar 

  69. Pelosi G, Fasullo M, Leon ME, et al. CD117 immunoreactivity in high-grade neuroendocrine tumors of the lung: a comparative study of 39 large-cell neuroendocrine carcinomas and 27 surgically resected small-cell carcinomas. Virchows Arch 2004;445:449–455.

    Article  PubMed  Google Scholar 

  70. Rossi G, Cavazza A, Marchioni A, et al. Kit expression in small cell carcinomas of the lung: effects of chemotherapy. Mod Pathol 2003;16:1041–1047.

    Article  PubMed  Google Scholar 

  71. Hibi K, Takahashi T, Sekido Y, et al. Coexpression of stem cell factor and the c-kit genes in small-cell lung cancer. Oncogene 1991;6:2291–2296.

    CAS  PubMed  Google Scholar 

  72. Rygaard K, Nakamura T, Spang-Thomsen M. Expression of the protooncogene c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor in SCLC cell lines and xenografts. Br J Cancer 1993;67:137–146.

    Google Scholar 

  73. Krystal GW, Hines SJ, Organ CP. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res 1996;56:370–376.

    CAS  PubMed  Google Scholar 

  74. Tamborini E, Bonadiman L, Negri T, et al. Detection of overexpression and phosphorylation wild-type Kit receptor in surgical specimens of small cell lung cancer. Clin Cancer Res 2004;10:8214–8219.

    Article  CAS  PubMed  Google Scholar 

  75. Maulik G, Shrikhande A, Kijima T, et al. Role of the hepatocyte growth factor receptor, c-Met, in the oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev 2002;13:41–59.

    Article  CAS  PubMed  Google Scholar 

  76. Ma PC, Maulik G, Christensen J, et al. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 2003;22:309–325.

    Article  CAS  PubMed  Google Scholar 

  77. Trusolino L, Comoglio PM. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nature Rev 2002;2:289–300.

    Article  CAS  Google Scholar 

  78. Maulik G, Kijima T, Ma PC, et al. Modulation of the c-met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res 2002;8:620–627.

    CAS  PubMed  Google Scholar 

  79. Ma PC, Kijima T, Maulik G, et al. C-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 2003;63:6272–6281.

    CAS  PubMed  Google Scholar 

  80. Wang WL, Healy ME, Sattler M, et al. Growth inhibition and modulation of kinase pathways on small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI571. Oncogene 2000;19:3521–3528.

    Article  CAS  PubMed  Google Scholar 

  81. Krystal GW, Honsawek S, Litz J, et al. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res 2000;6:3319–3326.

    CAS  PubMed  Google Scholar 

  82. Krystal GW, Honsawek S, Kiewlich D, et al. Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells. Cancer Res 2001;61:3660–68.

    CAS  PubMed  Google Scholar 

  83. Abrams TJ, Lee LB, Murray LJ, et al. SU11248 inhibits KIT and platelet-derived growth factor receptor β in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003;2:471–478.

    CAS  PubMed  Google Scholar 

  84. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139–145.

    CAS  PubMed  Google Scholar 

  85. Bondzi C, Litz J, Dent P, et al. Src family kinase activity is required for Kit-mediated mitogen-activated protein (MAP) kinase activation; however, loss of functional retinoblastoma protein makes MAP kinase activation unnecessary for growth of small cell lung cancer cells. Cell Growth Differ 2000;11:305–314.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, CHU de Grenoble Albert Michallon, Lung Cancer Research Group, INSERM U578, Grenoble, France

    Elisabeth Brambilla MD

Authors
  1. Elisabeth Brambilla MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pathology, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA

    Dani S. Zander MD

  2. Institute of Pathology, Laboratories for Molecular Cytogenetics, Medical University of Graz, Graz, Austria

    Helmut H. Popper MD

  3. Department of Pathology, University of Texas Health Science Center, San Antonio, TX, USA

    Jaishree Jagirdar MD

  4. Weill Medical College of Cornell University, New York, NY

    Abida K. Haque MD

  5. Department of Pathology, San Jacinto Methodist Hospital, Baytown, TX, USA

    Abida K. Haque MD

  6. Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY

    Philip T. Cagle MD  & Roberto Barrios MD  & 

  7. The Methodist Hospital, Houston, TX, USA

    Philip T. Cagle MD  & Roberto Barrios MD  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Science+Business Media, LLC.

About this chapter

Cite this chapter

Brambilla, E. (2008). Small Cell Carcinoma. In: Zander, D.S., Popper, H.H., Jagirdar, J., Haque, A.K., Cagle, P.T., Barrios, R. (eds) Molecular Pathology of Lung Diseases. Molecular Pathology Library, vol 1. Springer, New York, NY. https://doi.org/10.1007/978-0-387-72430-0_28

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-72430-0_28

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-72429-4

  • Online ISBN: 978-0-387-72430-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation